Herpes Zoster Treatments: Results of a Clinical Trial Relative to the Use of Rifamycin SV versus Neuramide

1984 ◽  
Vol 12 (4) ◽  
pp. 255-260 ◽  
Author(s):  
L Bruni ◽  
G Tagliapietra ◽  
P Innocenti
Keyword(s):  
Clinical Trial ◽  
Herpes Zoster ◽  
Clinical Study ◽  
Statistical Tests ◽  
Burning Sensation ◽  
Rifamycin Sv ◽  
Controlled Clinical Study

The authors describe a controlled clinical study in which rifamycin SV 250 mg intramuscularly and topical b.i.d. was compared to intramuscular neuramide b.i.d. plus, where necessary, other drugs (antibiotics, polivitamins, analgesics, etc.) for the treatment of two groups of thirty randomly selected patients suffering from herpes zoster. In all patients the symptoms were controlled by both treatments but statistical tests revealed that rifamycin SV was able to heal pain (p < 0·05), vesicles, crusts and burning sensation (p < 0·1) faster than neuramide. Furthermore, by the seventh day of therapy, the authors found that rifamycin SV reduced the intensity of both pain and erythema (p < 0·01 for pain; p < 0·05 for erythema) more than neuramide.

Preliminary Results of a Clinical Trial Relative to the Use of Rifamycin SV in the Treatment of Herpes Zoster

1980 ◽  
Vol 8 (1) ◽  
pp. 1-6 ◽  
Author(s):  
L Bruni ◽  
A Califano ◽  
G Angelis De ◽  
A Montagnani ◽  
M Pisani ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Herpes Zoster ◽  
Clinical Evaluation ◽  
Intramuscular Injection ◽  
Partial Evaluation ◽  
Controlled Clinical Trial ◽  
Statistical Calculation ◽  
Routine Treatment ◽  
Preliminary Results ◽  
Rifamycin Sv

In a controlled clinical trial undertaken in ten Italian centres, rifamycin SV was compared to associations of various drugs such as erythromycin, aureomycin, multivitamin preparations, etc, in the treatment of herpes zoster. Up to now 144 patients, suffering from herpes zoster at different localizations, were divided into three groups and randomly given either rifamycin SV by intramuscular injection and topically, or rifamycin SV by injection only, or the routine treatment used at the particular centre in question. To evaluate the effectiveness of the treatments, the presence of subjective and objective symptoms was determined before treatment started and daily thereafter. The duration, in days, of the most important symptoms, such as erythema, vesicles, scabs and pain, was considered for this partial evaluation. All the above-mentioned symptoms constantly showed a shorter duration in the two groups treated with rifamycin SV compared to the group treated with other therapies, with differences as significant on statistical calculation as they were important on the level of a clinical evaluation of the disease's course.

scholarly journals A CLINICAL STUDY OF SHILAJEET VATI IN PRAMEHA PURVARUPA (PRE-DIABETIC STATE)

2021 ◽  
Vol 9 (11) ◽  
pp. 2665-2670
Author(s):  
Esha Dhiman ◽  
Neetu Jha ◽  
Pradip Kumar Panda ◽  
Utkalini Nayak ◽  
Vinod Chandra Singh
Keyword(s):  
Clinical Trial ◽  
Clinical Study ◽  
Plasma Glucose ◽  
Postprandial Glucose ◽  
Burning Sensation ◽  
Excessive Sweating ◽  
Average Percentage ◽  
Objective Parameter ◽  
Trial Drug ◽  
Paired T Test

Introduction- The incidence of Prameha is increasing rapidly because of changes in dietetic habits and lifestyle. If the Prameha Purvarupa (Pre-diabetic) clinical features are treated by formulation Shilajeet is recommended in Ayurvedic Classics, proven efficacious and widely practised in the management of Prameha (Diabetes). Materi- als and methods- 30 patients from OPD and IPD of Govt. Ayurvedic College & Hospital, Balangir, fulfilling the Subjective and Objective Parameters were registered for the clinical trial. After diagnosis, they were under trial with Ayurvedic formulation Shilajeet Vati treated in a dose of 2 Vati (500mg each) twice daily empty stomach, for a period of 30 days with Ushna Jala. The assessment of subjective and objective parameters was evaluated on the 10th, 20th and 30th day from the day of initiation of trial up to 30 days in order to find the efficacy of the trial by statistical paired ‘t’ test. Observation and results- The average percentage of improvement in subjective parame- ter Prabhuta Mutrata (quantity) 71.43%, Prabhuta Mutrata (frequency) 77.78%, Pipasa (increased thirst) 72.73%, Kshudha (excessive appetite) 72.22%, Kara-pada Daha (burning sensation in hand and feet) 73.81%,Kara-pada Suptata (numbness of hand and feet) 80%, Sweda Pravritti (excessive sweating) 83.33%, Mukha Sho- sha (dry mouth) 79.17%, Mukha Madhurya (sweetness in mouth) 77.78%, Sheeta Priyata (liking for cold things) 80% and Madhura Shukla Mutrata (sweetness in urine) 100% and in objective Parameter fasting plasma glucose 68.89%, postprandial glucose 81.11%, HbA1c 73.33%. It has been observed that the trial drug patients are highly significant (p<0.001) to reduce both Subjective and Objective parameters after 30 days of treatment. Discussion and Conclusion- Prameha is a Kapha Pradhana Tridoshaja Vyadhi in which Meda is a Pradhana Dushya. The drug showed a potent Pramehahar effect which is evident from the reduction in the Subjective Parameter of Prameha and objective parameter of the levels of FBS, PPBS and HbA1c in patients. No side effect was noticed during the clinical study of Shilajeet Vati. Keywords: Prameha, Diabetes, Shilajeet Vati.

Entergastrone Parenterally in the Treatment of Peptic Ulcer: A Controlled Clinical Study

1951 ◽  
Vol 17 (1) ◽  
pp. 35-38 ◽  
Author(s):  
Frank C. Bone ◽  
Chester Cassel ◽  
Julian M. Ruffin ◽  
Robert J. Reeves
Keyword(s):  
Peptic Ulcer ◽  
Clinical Study ◽  
Controlled Clinical Study
Sign in / Sign up

Export Citation Format

Share Document